PIKTOR
phase 2drug program · high · Wed Apr 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
All-oral multi-node inhibition of the PI3K/AKT/mTOR pathway by simultaneously targeting PI3K-alpha, mTORC1, and mTORC2 for cancers including endometrial cancer and HR+/HER2- advanced or metastatic breast cancer.
Combination of sapanisertib and serabelisib, evaluated with paclitaxel and an insulin-suppressing diet substudy in advanced/recurrent endometrial cancer, and with fulvestrant and/or other anticancer therapies in HR+/HER2- advanced/metastatic breast cancer.
Phase 1b/2 breast cancer trial published on ClinicalTrials.gov on 2026-04-01; Phase 2 endometrial cancer trial published on 2024-12-12.
Preclinical models showed serabelisib plus sapanisertib suppressed PI3K/AKT/mTOR signaling more effectively than single-node inhibitors; sapanisertib, serabelisib plus paclitaxel/insulin-suppressing diet achieved complete inhibition of tumor growth or tumor regression in xenograft models.
Sapanisertib for NFE2L2-mutated and wild-type squamous non-small cell lung cancer
phase 2drug program · medium · Thu Jul 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate sapanisertib monotherapy in biomarker-defined relapsed or refractory squamous non-small cell lung cancer populations with NFE2L2-mutated or wild-type disease.
Multicenter, randomized, open-label Phase 2 study of sapanisertib monotherapy in two cohorts: NFE2L2-mutated sqNSCLC and NFE2L2-wild-type sqNSCLC.
ClinicalTrials.gov record published on 2022-07-21.
Medical food for metastatic colorectal cancer
undisclosedconsumer product · high · Wed Apr 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Dietary management of metastatic colorectal cancer using a medical food restricted in specific amino acids alongside routine second-line drug therapy.
Single-arm study evaluating tolerability and cancer markers in subjects receiving a specially designed amino-acid-restricted medical food with fluoropyrimidine and oxaliplatin with or without bevacizumab.
ClinicalTrials.gov record published on 2022-04-27.
Serabelisib plus insulin-suppressing diet with or without nab-paclitaxel
undiscloseddrug program · medium · Fri Apr 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate whether combining serabelisib with an insulin-suppressing diet, with or without nab-paclitaxel, can improve safety, tolerability, and anticancer activity in advanced solid tumors with PIK3CA mutations.
Clinical study of serabelisib, an investigational PI3K inhibitor, combined with an insulin-suppressing diet and optionally nab-paclitaxel.
ClinicalTrials.gov record published on 2022-04-22.
Medical food for advanced/metastatic pancreatic cancer
undisclosedconsumer product · high · Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Dietary management of locally advanced unresectable or metastatic pancreatic adenocarcinoma using a medical food restricted in specific amino acids alongside routine first-line therapy.
Single-arm study evaluating tolerability and markers of pancreatic cancer in subjects receiving a specially designed amino-acid-restricted medical food with gemcitabine and nab-paclitaxel.
ClinicalTrials.gov record published on 2021-12-21.
IEM
undisclosedother · low
Listed as a pipeline program, but no objective details are provided in the supplied material.
Undisclosed.
Listed in the supplied site analysis pipeline list.
NEAAR
undisclosedother · low
Listed as a pipeline program, but no objective details are provided in the supplied material.
Undisclosed.
Listed in the supplied site analysis pipeline list.
